Fluticasone furoate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fluticasone furoate
Fluticasone furoate.svg
Systematic (IUPAC) name
(6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • C for Intranasal
Routes of
administration
Intranasal
Legal status
Legal status
Pharmacokinetic data
Bioavailability 0.51% (Intranasal)
Protein binding 91%
Metabolism Intranasal
Hepatic (CYP3A4-mediated)
Biological half-life 10 hours
Excretion Renal
Identifiers
CAS Number 80474-14-2
ATC code R01AD12 (WHO) R03BA09 (WHO)
PubChem CID 9854489
DrugBank DB00588
ChemSpider 8030195
UNII JS86977WNV YesY
ChEBI CHEBI:74899
ChEMBL CHEMBL1676
Chemical data
Formula C27H29F3O6S
Molar mass 538.576 g/mol

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis administered by a nasal spray.[1]

The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.[2] As of 2015, it is also approved for the treatment of asthma. [3]

See also[edit]

References[edit]